12:07 PM
 | 
Jul 03, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CytomX begins Phase I/II of CX-2009 in solid tumors

CytomX Therapeutics Inc. (NASDAQ:CTMX) began the open-label, U.S. Phase I/II PROCLAIM-CX-2009 trial to evaluate CD166 PDC (CX-2009) in about 150 patients with metastatic or locally advanced unresectable solid tumors. The trial will recruit patients with...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >